Others studies have shown that FABP4 plasma concentrations are increased in patients with obesity, metabolic syndrome (MS), type 2 diabetes (T2D), familial combined hyperlipidemia, lipodystrophy syndromes and cardiovascular disease [10]–[15]. Here, FABP4 is linked to metabolic syndrome.